<DOC>
	<DOCNO>NCT02525029</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) Pregnyl® give combination standard immunosuppressive therapy pediatric adult patient high-risk ( Arm 1 ) refractory/dependent ( Arm 2 ) aGVHD .</brief_summary>
	<brief_title>Study Pregnyl Adjunct Therapy High-Risk Refractory Acute GVHD</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>Acute graft versus host disease ( GVHD ) fit one follow category : HighRisk aGVHD ( ARM 1 ) : Pediatric adult ( age 1276 year ) HCT recipient highrisk acute GVHD , determine refine MN acute GVHD risk score : http : //z.umn.edu/MNAcuteGVHDRiskScore . Patients arm must start treatment within first 7 day onset highrisk aGVHD . SteroidRefractory aGVHD ( ARM 2 ) : Pediatric adult ( age 1276 year ) HCT recipient grade IIIV steroid refractory steroiddependent acute GVHD , define one following : No response acute GVHD least 4 day systemic corticosteroid least 2 mg/kg prednisone equivalent Progression acute GVHD within 3 day systemic corticosteroid least 2 mg/kg prednisone equivalent Failure improve least grade II acute GVHD 14 day systemic corticosteroid , initial dos least 2 mg/kg prednisone equivalent Flare acute GVHD least grade II/IV severity despite taper dose steroid &gt; 0.5 mg/kg/day . Adequate organ function study enrollment define : Renal : 1.73m2Serum creatinine ≤2.5x upper limit normal ( ULN ) Cardiac : Left ventricular ejection fraction ( LVEF ) ≥ 35 % Voluntary write consent ( adult parent/guardian minor assent 12 17 year old ) Progressive malignancy Diagnosis hormone responsive malignancy Uncontrolled infection initiation protocol treatment Current thromboembolic disease require fulldose anticoagulation patient receive pharmacologic prophylaxis thromboembolic disease eligible Active recent ( within prior 3 month ) thrombus , irrespective anticoagulation status Pregnancy assess baseline blood hCG level Unwilling unable stop supplemental sex hormone therapy ( estrogen , progesterone , and/or testosterone preparation ) Women men childbearing potential unwilling take adequate precaution avoid pregnancy start protocol treatment 28 day last treatment</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GVHD</keyword>
</DOC>